Zepp Health: A Phenomenal Growth Story To Buy The Dip In

Zepp Health, which has pivoted away from Xiaomi branding and moved its HQ to the Netherlands, delivered a strong Q3 with revenue up 78% y/y to $75.8m—driven by the $399 T‑Rex 3 Pro launch and channel inventory loading—while guiding Q4 growth to 38–45% y/y and flagging some sales pushed into Q4 by supply constraints and a typhoon. The company is showing improving unit economics (GAAP gross margin +2pp to 38%), reached positive EBIT of $0.7m (1% margin) on flat GAAP opex, and has secured memory supply to protect margins. At ~ $24 a share Zepp trades with a market cap of $353.8m, pro forma net cash produces an enterprise value of $133.2m, and a conservative FY26 scenario (≈$273m revenue, 3% adj. EBIT) implies ~16.2x EV/adj. EBIT while the stock trades at <1x revenue versus Garmin at 4.7x—presenting a value case for buyers, though competition from Apple/Garmin, thin margins and small‑cap international risks remain material.

Analysis

Zepp Health reported Q3 revenue up 78% year-over-year to $75.8 million, accelerating from 46% y/y in Q2, driven by front-loaded sell-in for the $399 T‑Rex 3 Pro launch and channel inventory loading. The company flagged supply constraints on the $99.99 Helio Strap and a typhoon that shifted some demand into Q4, while guiding Q4 growth to 38–45% y/y—consistent with management’s expectation that part of Q3 strength was timing-related.

Profitability metrics show improvement: GAAP gross margin rose two percentage points to 38% and EBIT reached $0.7 million (1% margin), a 28-point improvement versus the prior-year quarter, with GAAP operating expenses held flat at $29.8 million. Management says it secured memory at favorable prices and increased inventory to mitigate tariff risk, actions that support margin stability if end-customer sell‑through remains healthy.

Valuation appears constructive at current share prices near $24 with a market cap of $353.8 million and a pro forma enterprise value of $133.2 million after netting $337.7 million cash against $117.1 million debt. A conservative FY26 scenario (~$273 million revenue, 3% adj. EBIT ≈ $8.2 million) implies ~16.2x EV/adj. EBIT and <1x revenue versus Garmin at 4.7x, but material risks include entrenched competition (Apple/Garmin), thin margins and small‑cap international execution exposure.

Key Decisions for Investors

• Consider a selective buy on material weakness given 78% y/y top-line acceleration, positive EBIT and a net cash-heavy balance sheet, size positions modestly due to small‑cap execution risk
• Monitor Q4 end-customer sell-through versus channel sell-in and the recovery of Helio Strap supply as the key near-term catalysts that will validate the Q3-driven revenue surge
• Reassess position if gross margins decline or operating expenses rise from current disciplined levels; use a 16–20x EV/adj. EBIT band as a valuation guide versus peers and remain mindful that Zepp trades at <1x revenue while peers trade materially higher
• Limit downside with position sizing or protective hedges given competitive pressure from Apple/Garmin, potential tariff/supply disruption, and the concentrated product-cycle exposure from recent launches